Thursday, 29 July 2010

More on patentability of medicines from Brazil

Few days back we brought you the news that INPI was debating with other sectors (pharmaceutical, non-profit organisations, education, among others) the criteria of patentability in the field of medicines.

Today, the INPI web page published that the meeting was to provide technical guidance for examining patents in the pharmaceuticals segment. According to INPI, “guidelines for the technical examination of patent applications are dynamic and try to adapt to changing technology, based on the Law of Industrial Property, LPI 9.276/96.”

Among the issues discussed were: conditions for patentability; Markush formula; Patents selection; polymorphism; second medical use; compositions / formulations / combinations; and isomers.

1 comment:

anon said...

Brazil's patent law involves the Ministry of Health in examining pharmaceutical patents. Where the Ministry of Health and the INPI most disagree is over the examination of how to examine precisely the sorts of incremental pharmaceutical innovations mentioned here.